2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Infectious Diseases, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, APL, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5144 Outcomes of patients with Blastic Plasmacytoid dendritic cell neoplasm undergoing Allogeneic Hematopoietic Stem cell transplantation

Hannah Goulart, MD, Denai Milton2, Qaiser Bashir, MD3, Uday Popat, MD, MBA4, Partow Kebriaei, MD5, Chitra Hosing, MD6, Issa F. Khouri, MD7, Betul Oran, MD8, Gheath Alatrash, PhD9, Amin Alousi, MD10, Rohtesh Mehta, MD, MPH11, Naval Daver, MD12, Sanam Loghavi, MD13, Nitin Jain, MD14, Richard Champlin15, Guillermo Garcia-Manero, MD16, Elizabeth Shpall, MD17, Muzaffar Qazilbash, MD18, Naveen Pemmaraju, MD19
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background 

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with historically poor outcomes. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative treatment for eligible patents, there are limited data describing post-allo-HSCT outcomes in BPDCN. In this report, we describe the outcomes of a large cohort of patients with BPDCN who underwent allo-HSCT at our institution.  

Methods 

We performed a retrospective analysis on patients with BPDCN who underwent allo-HSCT at our institution between September 2000 and June 2026. The primary endpoints were overall survival (OS), progression free survival (PFS), and the cumulative incidence of non-relapse mortality (NRM).  

Results  

A total of 44 patients were included, with a median age of 58 years (range, 16 – 81) at the time of allo-HSCT. Twenty (45%) patients were older than 60 years, and 86% were male. Overall, 10 patients (23%) had skin only involvement, 11 patients (25%) had central nervous system involvement, and 31 (71%) had involvement of >2 organs, including bone marrow and lymph nodes. For induction therapy, 4 patients (9%) received tagraxofusp alone, 9 (20%) received pivekimab alone, and 31 (70%) received chemotherapy with or without tagraxofusp. At the time of allo-HCT, 30 patients (68%) were in first complete remission (CR1), 10 (23%) were in first relapse (Rel1), and 4 (9%) were beyond Rel1.  

The most common preparative regimens were fludarabine plus busulfan-based (59%) and fludarabine plus melphalan-based (32%).  Donors included 10/10 matched unrelated donors (19, 44%), matched sibling donors (13, 30%), haploidentical donors (7, 16%), and mismatched unrelated or cord blood donors (4, 9%). The graft source was peripheral blood (PB) in 34 patients (77%), bone marrow in 7 patients (16%), and cord blood in 3 (7%). Graft-versus-host disease (GVHD) prophylaxis consisted of post-transplant cyclophosphamide, tacrolimus and mycophenolate mofetil in 36 patients (84%) and tacrolimus and methotrexate in 7 (16%). The cumulative incidence of NRM was 16% at 100 days and 26% at 1 year. Age >60 years (HR: 11.20, p=0.013) and cord blood vs. PB as graft source (HR: 32.11, p<0.001) were associated with significantly higher NRM on multivariate analyses. The cumulative incidence of grade >2 acute GVHD was 29%, and the 2-year incidence of limited or extensive chronic GVHD was 24%. Three patients developed veno-occlusive disease (VOD), including one grade III and two grade V, at a median of 11 days (range, 9 – 24) post allo-HSCT.  

With a median follow-up from allo-HSCT of 26.7 months (0.95 CI 0.4 – 160.3 months), the estimated 2-year PFS and OS rates were 60% and 64% respectively. Patients transplanted in Rel1 had a significantly shorter OS compared to those in CR1 (HR 3.11, p=0.03). Among patients transplanted in CR1, the estimated 5-year PFS and OS 1 were 68% and 67%, respectively.  

Conclusion 

In one of the largest single-center series of patients with BPDCN who underwent allo-HSCT, we showed durable remission and an estimated 5-year survival of 67% in patients who underwent allo-HCT in CR1. Ongoing efforts are focused on optimizing patient selection, incorporating novel induction strategies, and reducing transplant-related mortality to further improve the outcomes.   

Hannah Goulart, MD: No relevant conflicts of interest to declare.